IL91649A - A polydoma that produces, produces and uses two specific hybrid monoclonal antibodies against fibrin and pro-urokines - Google Patents

A polydoma that produces, produces and uses two specific hybrid monoclonal antibodies against fibrin and pro-urokines

Info

Publication number
IL91649A
IL91649A IL9164989A IL9164989A IL91649A IL 91649 A IL91649 A IL 91649A IL 9164989 A IL9164989 A IL 9164989A IL 9164989 A IL9164989 A IL 9164989A IL 91649 A IL91649 A IL 91649A
Authority
IL
Israel
Prior art keywords
antibody
fibrin
tpa
prourokinase
hybridoma
Prior art date
Application number
IL9164989A
Other languages
English (en)
Hebrew (he)
Other versions
IL91649A0 (en
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of IL91649A0 publication Critical patent/IL91649A0/xx
Publication of IL91649A publication Critical patent/IL91649A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL9164989A 1988-09-27 1989-09-15 A polydoma that produces, produces and uses two specific hybrid monoclonal antibodies against fibrin and pro-urokines IL91649A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP24354488 1988-09-27
JP30192588 1988-11-28
JP6294089 1989-03-14
JP16487389 1989-06-27
JP20893689A JP3177776B2 (ja) 1988-09-27 1989-08-11 ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤

Publications (2)

Publication Number Publication Date
IL91649A0 IL91649A0 (en) 1990-04-29
IL91649A true IL91649A (en) 1994-10-21

Family

ID=27523741

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9164989A IL91649A (en) 1988-09-27 1989-09-15 A polydoma that produces, produces and uses two specific hybrid monoclonal antibodies against fibrin and pro-urokines

Country Status (15)

Country Link
US (1) US5506135A (fr)
EP (1) EP0363712B1 (fr)
JP (1) JP3177776B2 (fr)
KR (1) KR900004351A (fr)
CN (1) CN1041783A (fr)
AR (1) AR242832A1 (fr)
AT (1) ATE140930T1 (fr)
AU (1) AU628857B2 (fr)
DE (1) DE68926899T2 (fr)
DK (1) DK474189A (fr)
FI (1) FI894551A (fr)
HU (1) HUT55445A (fr)
IL (1) IL91649A (fr)
NO (1) NO893818L (fr)
PT (1) PT91808B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068322A1 (en) * 1988-04-18 2003-04-10 Immunomedics, Inc. Methods of antibody-directed enzyme-prodrug therapy
TW212184B (fr) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
JPH0576385A (ja) * 1990-12-18 1993-03-30 Takeda Chem Ind Ltd キメラ抗体およびその用途
AU665758B2 (en) * 1991-04-26 1996-01-18 Surface Active Limited Novel antibodies, and methods for their use
US10227407B2 (en) 2013-10-10 2019-03-12 Yukinari Kato Anti-podoplanin antibody
SG11201910113PA (en) * 2017-05-02 2019-11-28 Nat Cancer Center Japan Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714681A (en) * 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
ES521370A0 (es) * 1982-04-12 1985-04-16 Hybritech Inc Un procedimiento para obtener un polidoma.
US4916070A (en) * 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
JP2635343B2 (ja) * 1986-04-14 1997-07-30 ザ・ジェネラル・ホスピタル・コーポレーション ヘテロ二官能性抗体および利用方法

Also Published As

Publication number Publication date
KR900004351A (ko) 1990-04-12
AR242832A1 (es) 1993-05-31
FI894551A (fi) 1990-03-28
DK474189D0 (da) 1989-09-26
US5506135A (en) 1996-04-09
JPH03103175A (ja) 1991-04-30
NO893818D0 (no) 1989-09-26
AU628857B2 (en) 1992-09-24
IL91649A0 (en) 1990-04-29
FI894551A0 (fi) 1989-09-26
EP0363712A2 (fr) 1990-04-18
DE68926899D1 (de) 1996-09-05
JP3177776B2 (ja) 2001-06-18
PT91808A (pt) 1990-03-30
DK474189A (da) 1990-03-28
CN1041783A (zh) 1990-05-02
ATE140930T1 (de) 1996-08-15
EP0363712A3 (en) 1990-08-16
EP0363712B1 (fr) 1996-07-31
NO893818L (no) 1990-03-28
PT91808B (pt) 1995-05-31
HUT55445A (en) 1991-05-28
DE68926899T2 (de) 1997-01-02
AU4174789A (en) 1990-04-05

Similar Documents

Publication Publication Date Title
EP0450479B1 (fr) Anticorps monoclonaux bispécifiques, leur production et utilisation
EP0419574B1 (fr) Anticorps monoclonaux contre la region a chaine legere du facteur humain xii et procedes de preparation et d'utilisation de ces anticorps
KR100585473B1 (ko) 혈액 응고를 억제하기 위한 항체 및 그의 사용 방법
US20090252726A1 (en) Antibodies for inhibiting blood coagulation and methods of use thereof
KR20050040844A (ko) 혈액 응고를 억제하기 위한 항체 및 이의 사용 방법
JPH05304992A (ja) ハイブリッド・モノクローナル抗体および抗体含有薬剤
EP0241907A2 (fr) Anticorps hétérobifonctionnels et méthode d'utilisation
EP0363712B1 (fr) Anticorps monoclonaux hybrides, leur production et utilisation
EP0139447B1 (fr) Procéde pour la préparation du Zymogène d'urokinase
US5620688A (en) Methods of inhibiting the activation of Factor XIII
US5453269A (en) Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
Kurokawa et al. Enhanced fibrinolysis by a bispecific monoclonal antibody reactive to fibrin and tissue plasminogen activator
Hayzer et al. Conjugation of plasminogen activators and fibrin-specific antibodies to improve thrombolytic therapeutic agents
US7247453B1 (en) Calcium binding recombinant antibody against protein C
EP0513778A2 (fr) Anticorps monoclonaux hybrides et compositions les contenant
EP0491351A2 (fr) Anticorps chimériques et leur utilisation
JPH02142494A (ja) 抗ウロキナーゼモノクローナル抗体
JPS61186399A (ja) 抗ヒトアンジオテンシン変換酵素抗体
JPH04218389A (ja) 二重特異性抗体および抗体含有薬剤
Charpie Monoclonal antibodies specific for single-chain urokinase: applications in targeted thrombolysis
CA2056118A1 (fr) Anticorps monoclonaux qui lient la proteine fixatrice du mannose
JPH0575394B2 (fr)
JPH0995500A (ja) モノクローナル抗体および血栓溶解促進剤

Legal Events

Date Code Title Description
RH Patent void